Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer

Current Oncology

Volumn 20, Issue 2, 2013, Pages

  Cheema, Parneet K ^a   Burkes, R L ^b,c  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Endpoint; Non small cell lung cancer; Overall survival; Progression free survival

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; VANDETANIB; VINCA ALKALOID;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HUMAN; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS;

EID: 84875875064     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1226     Document Type: Article

References (53)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004;54:8-29.
2. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
4. United States, Department of Health and Human Services, Food and Drug Administration (fda). Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics. Bethesda, MD: fda; 2011. [Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM259421.pdf; cited February 5, 2013]
5. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012;30:1030-3.
6. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002;3:4.
7. Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 2008;24:371-83.
8. Sherrill B, Amonkar M, Wu Y, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008;99;1572-8.
9. Kay A, Higgins J, Day AG, Meyer RM, Booth CM. Randomized controlled trials (rcts) in the era of molecular oncology. Methodology, biomarkers, and endpoints. Ann Oncol 2012;23:1646-51.
10. Sacher AG, Leighl NB. Shifting patterns in the interpretation of phase iii clinical trial outcomes in the treatment of advanced nsclc [abstract 6105]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82903; cited February 15, 2013]
11. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R. Review of oncology and hematology drug product approvals at the U.S. Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 2010;102:230-43.
12. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual-and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008;17:467-75.
13. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Therasse P. Measuring the clinical response: what does it mean? Eur J Cancer 2002;38:1817-23.
16. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase iii com-parative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:3390-9.
17. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase iii study of the Southwest Oncology Group. J Clin Oncol 1993;11:873-8.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
19. Lara PN Jr, Redman MW, Kelly K, et al. on behalf of the Southwest Oncology Group. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group Randomized Trials. J Clin Oncol 2008;26:463-7.
20. Mandrekar SJ, Qi Y, Hillman SL, et al. Endpoints in phase ii trials for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:3-9.
21. Buyse ME, Squifflet P, Laporte S, et al. Prediction of sur-vival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2, 838 patients randomized in 7 trials [abstract 8019]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail?_view&confID=55&abstractID=32835; cited January 9, 2013]
22. Douillard JY, Laporte S, Fossella F, et al. Comparison of docetaxel-and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;9:939-46.
23. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
24. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1416-23.
25. Reck M, von Pawel J, Zatloukal P, et al. Phase iii trial of cis-platin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non squamous non-small cell lung cancer: avail. J Clin Oncol 2009;27:1227-34.
26. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase iii trial (avail). Ann Oncol 2010;21:1804-9.
27. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study com-paring cisplatin plus gemcitabine with cisplatin plus peme-trexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
28. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): an open-label randomised phase iii trial. Lancet 2009;373:1525-31.
29. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (ipass). J Clin Oncol 2011;29:2866-74.
30. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemo-therapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
31. Han JY, Park K, Kim SW, et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8.
32. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European pa-tients with advanced EGFR mutation-positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
33. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog 3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
34. Misudomi T, Morita S, Tatabe Y, et al. Updated overall survival results of wjtog 3405, a randomized phase iii trial comparing gefitinib (g) with cisplatin plus docetaxel (cd) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (egfr) [abstract 7521]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93530; cited January 9, 2013]
35. Yang JC, Schuler MH, Yamamoto N, et al. lux-Lung 3: a randomized, open-label, phase iii study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations [abstract 7500]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91942; cited January 9, 2013]
36. Schiller JH, Harrington D, Belani CP, et al. on behalf of the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-9.
37. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression free survival. J Natl Cancer Inst 2009;101:1642-9.
38. Shepherd FA, Dancey J, Ramlau R, et al. Prospective random-ized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with plat-inum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
39. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
40. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemo-therapy. J Clin Oncol 2004;22:1589-97.
41. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best sup-portive care in previously treated patients with refractory ad-vanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evalu-ation in Lung Cancer). Lancet 2005;366:1527-37.
42. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (lux-Lung 1): a phase 2b/3 random-ized trial. Lancet Oncol 2012;13:528-38. [Erratum in: Lancet Oncol 2012;13:e186]
43. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase iii trial (zephyr). J Clin Oncol 2012;30:1114-21.
44. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-83.
45. Fidias PM, Dakhil SR, Lyss AP, et al. Phase iii study of imme-diate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009;27:591-8.
46. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.
47. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
48. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (paramount): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-55.
49. Paz-Ares L, De Marinis F, Dediu M, et al. paramount: final overall survival (os) results of the phase iii study of maintenance pemetrexed (pem) plus best supportive care (bsc) versus pla-cebo (plb) plus bsc immediately following induction treatmentwith pem plus cisplatin (cis) for advanced nonsquamous (ns) non-small cell lung cancer (nsclc) [abstract 7507]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94836; cited January 9, 2013]
50. Maroun JA. The significance of progression-free survival as an endpoint evaluating the therapeutic value of antineoplastic agents. Curr Oncol 2011;18(suppl 2):S3-4.
51. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl J Med 2010;363:733-42.
52. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinua-tion in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-303.
53. Pilz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (pfs) substitute overall survival (os) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res 2012;1:26-35.